[PP.35.31]

Objective: New drugs that inhibit angiogenesis, including Sunitinib, can cause arterial hypertension (HT). This side effect contributes to morbidity in these patients. It[Combining Acute Accent]s not well known how can be affected arterial blood pressure (BP) in hypertensive patients and in previosly non hypertensive ones. In this study we analyzed 18 patients who received Sunitinib in the past year, 2014.Design and method: We have collected data from the medical records of patients receiving sunitinib in the past year by renal carcinoma metastatic. We have analyzed demographics and clinical characteristics with emphasis on acumulative dose received, incidence of new HT onset, control of HT in hypertensive patients, medications received for BP control and hypertensive crisis. Results: Our sample has18 patients (70% male) with a mean age 7.7 ± 57’05 who received sunitinib. 44% were not-known-hypertensive patients prior to treatment, 37,5% of this group develop to hypertension (Fig 1). Among the known-hypertensive, 57’3% worsened their BP control (Fig 2). We found a 35% of patients who had hypertensive crisis which need emergency hospital attention. No hypertensive emergency were presented. To get BP control, at least two antihypertensive drugs were necessary to treat not previously known hypertensive patients. Previously hypertensive patients need to be adjusted his antihypertensive treatment in most of the cases to get BP control. No statistical significances were found between the accumulative dose of sunitinib and the degree of HT. Conclusions: Sunitinib can trigger hypertension in non-hypertensive patients and may worsen the degree of control of BP in previously hypertensive patients. Hypertensive crises may occur in 35% of patients. These findings were not associated with the cumulative dose of Sunitinib and were not statistically significant due to the small sample in our study. It[Combining Acute Accent]s necessary to analyzed more data in further studies.